Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Presents Update On Strategic Plan
The growing demand for generic pharmaceuticals as a means to expand access to affordable high-quality medicine and control healthcare costs will continue to drive the growth of the
The growing demand for generic pharmaceuticals as a means to expand access to affordable high-quality medicine and control healthcare costs will continue to drive the growth of the
Prolias has acquired technology from the University of Maryland Biotechnology Institute (UMBI). The new technology is expected to extend Prolias’ discovery platform, FioNA, by providing a platform for
BioMimetic Therapeutics (BioMimetic) has amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, effective December 31, 2009, for the supply of bulk rhPDGF-BB The
Watson Pharmaceuticals has confirmed that its subsidiary, Watson Laboratories has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its 50mg, 100mg, 150mg,
Actavis has launched the antihypertensive drug ‘Losartan’ on day one, as the patent expired in Switzerland. The product was launched by the company under its own name, and
Microbia, a producer of sustainable specialty ingredients and biomaterials, has achieved an important milestone in creating its line of naturally derived carotenoids for the food ingredient and nutritional
Forest Laboratories and Almirall have announced positive top-line results from ACCORD COPD I, a three-month phase III study comparing aclidinium 200ug and 400ug BID versus placebo. Aclidinium bromide
Under the terms of the agreement, MRS will incorporate ‘risk flags’ for hereditary breast cancer risk in their breast cancer tracking software. This will enable medical professionals at
Aetna acknowledge SpectraCell’s micronutrient testing as a valuable piece of the healthcare puzzle, changing the current paradigm of disease-care to true wellness-care and prevention. SpectraCell’s micronutrient testing provides
OncoMed and Fluidigm have formed a strategic collaboration for a new initiative to apply Fluidigm’s microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.